Provectus Biopharmaceuticals, Inc. announced the initiation of a preclinical study for its lead investigational drug, PV-10, in an orthotopic bladder cancer model. The study is being conducted by Translational Drug Development, LLC (TD2), with results expected in the first quarter of 2026.
This preclinical study will evaluate PV-10's performance across different treatment arms, including oral and intravesical monotherapy, as well as in combination with an anti-PD-1 checkpoint inhibitor. The design aims to generate translational data to inform future clinical development of PV-10 for bladder cancer.
Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus, stated that successful results from this research would allow the company to expand PV-10's investigational new drug application for site-specific and systemic administration. This initiative has the potential to broaden PV-10's immuno-oncology applications for solid tumor cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.